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Abstract 
Infants and young children with severe acute malnutrition (SAM) are treated with empiric broad-
spectrum antimicrobials. Parenteral ceftriaxone is currently a second-line agent for invasive 
infection. Oral metronidazole principally targets small intestinal bacterial overgrowth. Children with 
SAM may have altered drug absorption, distribution, metabolism and elimination. Population 
pharmacokinetics of ceftriaxone and metronidazole were studied, with the aim of recommending 
optimal dosing. Eighty-one patients with SAM (aged 2-45 months) provided 234 post-dose 
pharmacokinetic samples for total ceftriaxone, metronidazole and hydroxymetronidazole. 
Ceftriaxone protein binding was also measured in 190 of these samples. A 3-compartment model 
adequately described free ceftriaxone, with a Michaelis-Menten model for concentration and 
albumin dependent protein binding. A 1-compartment model was used for both metronidazole and 
hydroxymetronidazole, with only 1% of hydroxymetronidazole predicted to be formed during first-
pass. Simulations showed 80 mg/kg once daily of ceftriaxone and 12.5 mg/kg twice daily of 
metronidazole were sufficient to reach therapeutic targets. 
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Introduction 
In Sub-Saharan Africa, infants and young children with complicated severe acute malnutrition 
(SAM) requiring hospital admission have a 12 to >30% inpatient case fatality1, with bacterial 
infection being a common cause. As a result, the World Health Organization (WHO) recommends 
that all children admitted to hospital with SAM receive broad spectrum antimicrobial treatment, 
usually with a combination of a beta-lactam plus aminoglycoside antibiotics2. Recent studies 
suggest increasing antimicrobial resistance but there is no evidence for the efficacy of alternative 
first-line antimicrobial combinations in this context3. 
Ceftriaxone, a broad-spectrum third generation cephalosporin, is a potentially useful first-line 
treatment for children with SAM. It is inexpensive and, due to its long half-life, only requires once-
daily administration, which is important to over-stretched healthcare settings where children with 
SAM are usually managed. When assessing its likely antimicrobial efficacy, the free concentration 
needs to be considered since ceftriaxone protein binding is nonlinear, with higher total 
concentrations being associated with larger fraction unbound. Its nonlinear concentration effect is 
further compounded by increased free fraction with decreasing plasma proteins, most notably 
albumin. Models describing nonlinear ceftriaxone protein binding have been developed in special 
populations such those as in intensive care4. SAM is associated with potentially reduced available 
plasma proteins, and often commonly presents with edema, both of which may affect ceftriaxone 
disposition. 
In addition to sepsis, small intestinal bacterial overgrowth and intestinal parasitosis are implicated 
in malabsorption, diarrhea and reduced nutritional recovery in children with SAM. Empiric oral 
metronidazole, a nitroimidazole antibacterial active against a wide range of bacteria including 
anaerobes, is advocated by some experts5, and may aid long-term growth recovery6, but its 
efficacy for mortality and nutritional recovery are yet to be studied in an appropriately designed 
clinical trial. The pharmacokinetics of metronidazole in SAM may be altered with its half-life prior to 
nutritional rehabilitation being reported in one study as up to 23 hours7. Furthermore its major 
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hydroxy metabolite has around 65% activity compared with the parent drug8.  
Hydroxymetronidazole pharmacokinetics have yet to be studied in children with SAM.  
Here we report a study on ceftriaxone and metronidazole pharmacokinetics in order to define  
appropriate dosing for the sick, hospitalized infants and young children with SAM. This study forms  
the initial stage of the First Line Antimicrobials in Complicated Severe Acute Malnutrition  
(FLACSAM) trial (clinicaltrials.gov NCT03174236), which will compare ceftriaxone (+/-  
metronidazole) with standard-of-care antimicrobials (+/- metronidazole) in a 2x2 factorial design for  
outcomes including mortality and nutritional recovery. An important risk associated with  
unrestricted ceftriaxone use is selection for extended spectrum beta lactamase (ESBL) and  
resistance to other antibiotics classes. It will therefore be particularly important for the study of real- 
world resistance development to be done in the context of optimally efficacious ceftriaxone dosing.  
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Results 
Patients and demographics 
A total of 81 infants and young children with SAM were recruited in 3 centers in Kenya. A baseline 
sample was taken from all patients, and then 234 post dose samples were collected from which 
total ceftriaxone, metronidazole and hydroxymetronidazole was measured. Unbound ceftriaxone 
was also measured in 190 of these samples. In 12 patients the baseline sample contained 
metronidazole and/or hydroxymetronidazole, and in one patient ceftriaxone was detected in the 
baseline sample. These patients were excluded from the pharmacokinetic analysis of the drug 
detected in their baseline sample, but retained for analysis of the other drug. Vomiting following 
one of the metronidazole dose occurred in seven patients, whereas two vomited following two of 
the doses. The total number of metronidazole doses during PK sampling was 572 giving a vomiting 
rate per dose of 1.6%. Demographics and clinical presentation are given in Table 1. 
Pharmacokinetic structural models 
A 3-compartment model provided a slightly better fit than a 2 compartment model (𝛥 OFV -7.4) to 
total ceftriaxone, with unbound measurements predicted assuming instantaneous binding with a 
Michaelis-Menten model (see Methods). For the simultaneous modelling of metronidazole and 
hydroxymetronidazole, a 1-compartment disposition model was adequate for both, and adding a 
zero order lag to the first order absorption gave a significant improvement in fit (p<0.05). Allometric 
scaling9 was added a priori along with a fixed sigmoidal maturation function on clearance based on 
glomerular filtration maturation for ceftriaxone10 and CYP2A6 maturation11 for metronidazole. 
Neither maturation model improved fit (𝛥 OFV < 3.84) but nor was the fit worsened, and so they 
were retained in the model as biological priors for extrapolation. In the case of metronidazole, initial 
model building excluded patients who vomited within two hours of a dose, but including these 
patients did not noticeably change the goodness-of-fit, and the largest change in parameter 
estimate was a 15% decrease in clearance. Since one would expect lost dosing due to vomiting if 
anything to increase apparent clearance, it was decided to retain these samples. 
Hydroxymetronidazole was described using a semi-mechanistic model allowing formation from 
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both first-pass and circulating drug, the model with only formation from circulating drug giving a 
significantly worse fit (p<0.001). A low extraction ratio of around 1% indicated most 
hydroxymetronidazole is formed from systemic metronidazole. Both models terminated with 
successful covariance steps, and model parameters are reported in Table 2. NONMEM code and 
model diagnostics for both models are provided in the Supplementary Materials. 
Edema significantly affects disposition 
For both ceftriaxone and metronidazole adding edema as a covariate on body weight in the 
allometric model for volume improved fit. In the case of ceftriaxone, the largest drop in objective 
function (OFV) was associated with decreased apparent weight on volume parameters in the 
allometric model with any grade of edema of 26%. For metronidazole the effect of edema was less 
pronounced with largest OFV drop occurring with an edema score of 2 or more leading to a 
decrease in apparent weight of 17%. 
Ceftriaxone clearance associated with renal function and protein binding predicted from 
serum albumin 
Free ceftriaxone clearance was significantly (p<0.001) associated with age corrected serum 
creatinine12. Free ceftriaxone was modelled directly, with total ceftriaxone predicted by assuming 
instantaneous binding and a concentration-dependent Michaelis-Menten model. Albumin was 
found to significantly (p<0.001) improve the fit when added to the 𝐵𝑚𝑎𝑥 parameter in the Michaelis-
Menten model, with lower serum albumin being associated with higher fraction unbound. Figures 1 
and 2 show visual predictive checks for the ceftriaxone and metronidazole final models 
respectively. Basic goodness-of-fit plots, a plot of fraction unbound versus total concentration with 
different albumin concentrations, and a schematic of the final model are provided in Supplementary 
Materials. 
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Probability of target attainment to inform dosing  
Fraction time above MIC (𝑓𝑡 > 𝑀𝐼𝐶) for ceftriaxone free concentration over the first 24 hours was  
simulated for 50, 80 and 100 mg/kg once daily dosing (Figure 3). For metronidazole the sum of the  
free concentration and 0.65 multiplied by the free hydroxymetronidazole concentration was used to  
simulate twice daily dosing regiments of 10, 12.5 and 15 mg/kg with 𝑓𝑡 > 𝑀𝐼𝐶 and AUC:MIC ratio  
calculated for the 24 hour periods 0-24 hrs and 24-48 hrs (Figure 4). The effects of included  
covariates on pharmacodynamic target attainment are presented in Figure 5.  
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Discussion 
This is to our knowledge the first detailed pharmacokinetic study of ceftriaxone in infants and 
young children with SAM3, and we have also augmented the limited available data on oral 
metronidazole pharmacokinetics in this population7. Edema, a common feature of SAM, 
significantly affected the disposition of ceftriaxone, and to a lesser extent metronidazole, with 
patients having a lower volume of distribution than would be expected from their total body weight. 
This did not translate into marked changes in circulating concentrations or produce a clear 
indication of the need for dose reduction (Figure 5), indicating clearance is more important for 
𝑓𝑡 > 𝑀𝐼𝐶 than volume of distribution in this case. Whilst no other covariates were significant for 
metronidazole, in common with previous studies we found decreased ceftriaxone clearance with 
worsening renal function13 and also, as expected, the fraction unbound significantly related to 
serum albumin4. Again, as expected14, changes in albumin has no effect on free drug 
concentration or target attainment. As in previous studies15–17, rather than use a model-based 
estimate of creatinine clearance we used serum creatinine scaled by the age appropriate typical 
value12 to identify patients deviating from an expected normal value. This is a similar principle to 
using a creatinine clearance value scaled to 1.73 m2 but that approach only delineates size related 
changes in expected creatinine clearance, not age. In terms of the impact of covariates on target 
attainment, simulations showed that albumin was not an important predictor of free ceftriaxone 
whereas patients with low serum creatinine had reduced ceftriaxone target attainment (Figure 5). 
The degree of this reduction was however not sufficient to necessitate dose increases in these 
patients. 
In this study precise pharmacokinetic parameter estimates were obtained with low shrinkage (see 
Table 2)18 using only three post-dose samples. This is due to a careful sampling schedule, which 
although not defined with optimal design methods, followed the general principle of sampling close 
to the likely 𝐶𝑚𝑎𝑥 to give information on distribution, late samples aiming to cover at least three 
expected half-lives to inform on clearance, and samples in the expected absorption phase for oral 
metronidazole. By randomizing patients to different combinations of early, middle and late 
sampling points, in a similar manner to a previous antimicrobial study in this population19, study 
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invasiveness was minimized whilst maximizing information content. This approach exemplifies the 
benefits of careful study design, avoiding the problems that can be caused with opportunistic and 
scavenged sampling20. 
Unlike some ceftriaxone pharmacokinetic studies21 we measured both total and free ceftriaxone 
from patient samples, and under the assumption that only free ceftriaxone was available for 
distribution, elimination, and antimicrobial activity, it was modeled directly rather than being inferred 
from total concentrations4. Due to the expense of measuring free ceftriaxone, it was not performed 
in every sample and where possible we aimed to obtain free concentrations from an early and a 
late sample in order to maximize data on the concentration range from that individual. Previous 
studies have not directly modeled free ceftriaxone, rather the tendency has been to model total 
ceftriaxone and infer free concentrations from this. If only free ceftriaxone is available for 
distribution and elimination, modelling total ceftriaxone would appear to be problematic since its 
nonlinear protein binding means volume of distribution will change with total concentration. We 
used a method similar to that of a recent study on cefazolin24 whereby total concentration in the 
central compartment was used to predict free concentration and free fraction, and it was only the 
free fraction that was available for elimination and distribution. Full details of the model, including 
NONMEM code, are provided in the Supplementary Material. 
Comparing our model parameters with other studies is complicated by many reporting parameters 
for total ceftriaxone and a lack of standardization of age and weight (or size) scaling9. Our free 
ceftriaxone clearance estimate standardized to a 70 kg mature individual with normal creatinine for 
age and gender was 4.62 L/h. This estimate is slightly lower than patients without renal impairment 
in a recent report of adult intensive care patients (6.2 L/h), higher than the neonatal-reported value 
of 1.61 L/h/1.73 m2 25, but lower than the 14.86L/h reported in healthy adult volunteers26. Regarding 
protein binding, our dissociation constant (𝐾𝑑) of 22.9 mg/L is similar to the value (28.7 mg/L) that 
was recently reported by Schleibinger  4. No effect of adding maturation functions to clearance 
parameters in either the ceftriaxone or metronidazole models was found, most likely because most 
of our patients would be predicted close to the mature value by their age and we only had data in 
the upper part of the maturation curve. For example, our youngest patient had a postmenstural age 
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of 46 weeks, which is approximately the half-mature value in the renal clearance model10. The  
rationale for retaining maturation functions is to provide biological prior information in case the  
models were to be used for extrapolation to younger patients.  
When using the model for simulation of pharmacodynamic target attainment we chose not to follow  
the traditional method of defining a single target and simulating the probability of target attainment  
(PTA) against ascending MIC values. Our reasons for this are two-fold: firstly such plots tend to  
give measures of spread of target attainment across the population; secondly the preferred target  
may not be fixed, with recent work showing that different populations may require different  
𝑓𝑡 > 𝑀𝐼𝐶 values27. We therefore chose to plot the actual target (𝑓𝑡 > 𝑀𝐼𝐶 or 𝐴𝑈𝐶:𝑀𝐼𝐶) with  
ascending MIC values, along with important percentiles from the simulations. This therefore shows  
not just the simulated typical patient, but for example the 5th percentile shows the minimum target  
attainment expected in 95% of patients. We would suggest that presenting antimicrobial simulation  
data in this way (Figures 3 and 4) provides more information than traditional PTA curve.  
By parameterizing the model in terms of free ceftriaxone, simulations of free concentrations were  
therefore straightforward and the 𝑓𝑡 > 𝑀𝐼𝐶, which is the index usually found to correlate with  
antimicrobial activity28 was simulated for a range of MIC values (Figure 3). A common target for  
beta lactam antimicrobials is to achieve a 𝑓𝑡 > 𝑀𝐼𝐶 of at least 50% of the dosing interval, and  
typically Enterobacteriaciae with MICs below 1 mg/L were considered susceptible, although 2 mg/L  
is now a more common breakpoint, with MIC > 8 mg/L indicating the need to test for the presence  
of ESBL29. Our simulations show that for 50 mg/kg dosing there is a greater than 95% probability of  
having 50% of the dose interval with concentrations exceeding 2 mg/L and increasing the dose to  
80 mg/kg improves this to 95% of patients of patients having greater than 60% of the dose interval  
exceeding 2 mg/L, and greater than 80% of patients achieving 50% above 8 mg/L (the ESBL  
breakpoint).  
Including metronidazole formation form first-pass and circulating concentrations gave a 70.8 point  
lower objective function value than when only circulating concentrations were allowed to form  
metabolite, and hence it was retained despite the small fraction (around 1%) formed in this way. In  
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the standard parent metabolite model allowing formation from circulation and first-pass is not  
uniquely identifiable since the formation rate cannot be separated from the fraction metabolized30.  
Using the well-stirred hepatic metabolism model, the formation rate is bounded by liver plasma flow  
and hence the intrinsic clearance parameter is the only parameter estimated. This is a similar  
approach to that taken in a study of oseltamivir carboxylate formation from oseltamivir31, and gave  
a good description of our data (see Figure 2). Without intravenous data the model parameters  
estimated are however still apparent, since the total bioavailability is not identifiable. An  
investigation of parameter identifiability and parameter interpretation is provided in the  
Supplementary Materials. Including hydroxymetronidazole was important since it is known to have  
antimicrobial activity in its own right32. Our decision to sample patients up to 72 hours post first- 
dose based on previous data in this population7 was clearly justified as accumulation can be seen  
for both metronidazole and hydroxymetronidazole (Figure 2).  
The pharmacodynamic target of metronidazole in this setting is somewhat unclear. Whilst time  
above a MIC cut-off of 8 mg/L33 or AUC(0-24)/MIC of 708 have been proposed, and could  
potentially be used to justify once daily dosing along with the use of a loading dose, when treating  
small intestinal overgrowth it could be argued that local upper gastrointestinal tract concentrations  
maybe more important for efficacy. Taking our estimated absorption rate constant and assuming a  
gut lumen volume of 100 mL (dose taken with food/drink) a 12.5 mg/kg dose administered to an 8  
kg child would leave a local concentration of 7.3 mg/L prior to the next dose. Twice daily dosing  
would also give acceptable AUC and 𝑓𝑡 > 𝑀𝐼𝐶 target attainment (Figure 4). Although twice daily  
dosing requires higher volumes of suspension to be administered, only 1.6% of doses in this study  
were followed by the patient vomiting. It should however be noted that we did not find vomiting  
within 2 hours of a dose to affect metronidazole pharmacokinetic estimates when they were  
included in the analysis.  A dose of 12.5 mg/kg twice daily gives a total daily dose of 25 mg/kg,  
which is slightly higher than the current recommended dose (7.5 mg/kg three times, giving 22.5  
mg/kg/day).   
In conclusion, for children who are severely ill with complicated SAM, this study supports doses of  
IV ceftriaxone 80 mg/kg once daily, which is in line with recent WHO recommendations. Our  
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suggested dosing of oral metronidazole 12.5 mg/kg twice daily provides a simplified regime which 
should maintain efficacious upper gastrointestinal tract concentrations. 
Methods 
Patient recruitment 
A 3-centre open label Phase II PK study was undertaken in children aged 2-59 months with severe 
acute malnutrition (SAM). For children aged 6 to 59 months, SAM was defined as kwashiorkor 
(edematous malnutrition) or a middle upper arm circumference (MUAC) less than 11.5cm, or 
weight-for-height Z-score of less than -3. For children aged 1 to 5 months SAM was defined as 
kwashiorkor or MUAC less than 11cm or weight-for-height Z score less than -3. Infants with weight 
less than 2.5Kg were excluded. The study received favorable ethical review from the Kenya 
Medical Research Institute Review Committee, Nairobi, the Oxford Tropical Research Ethics 
Committee, Oxford, UK, and the Kenyan Expert Committee on Clinical Trials of the Pharmacy & 
Poisons Board, and is registered with clinicaltrials.gov (NCT02746276). Parents of eligible patients 
were approached for informed consent. 
Drug administration, sampling and assay 
Enrolled patients received ceftriaxone 50 mg/kg (or 100 mg/kg if meningitis suspected) 24 hourly 
by intravenous bolus (250 mg or 500 mg vials, Roche), and metronidazole 7.5 mg/kg 8 hourly by 
oral suspension (200 mg/5mL, Sanofi). PK samples were taken up to 72 hours following the first 
dose. A baseline PK sample was taken and then the first metronidazole dose followed by the first 
ceftriaxone dose. To minimise study invasiveness only 3 further PK samples were taken. Patients 
were randomised to one of 3 possible early, middle and late samples as follows: 
1. Early: 5 min, 30 min or 1 hr post first dose 
2. Middle: 2 hrs, 4hrs or 8 hrs post first dose 
3. Late: 24 hrs, 48 hrs or 72 hrs post first dose 
with exact dosing and sampling time recorded to the nearest minute. 
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Samples were analyzed for total ceftriaxone, metronidazole and hydroxymetronidazole. free 
ceftriaxone was also measured in a subset of samples, with preference given to the early and late 
time points. Full details on the assay were recently published by Ongas 35. Briefly, a reversed-
phase high-performance liquid chromatography method coupled with electrospray ionization mass 
spectrometry (HPLC–ESI-MS/MS) method was developed requiring 50 𝜇L of plasma for 
simultaneous ceftriaxone, metronidazole and hydroxymetronidazole quantification (a further 25 𝜇L 
was required for ultra filtration and free ceftriaxone quantification). The intra- and inter- run 
precision was less than 9% and the lower limits of quantification were 0.4, 0.05 and 0.02 𝜇 g/mL for 
ceftriaxone, metronidazole and hydroxymetronidazole respectively. 
Pharmacokinetic model building 
Unbound ceftriaxone was first analyzed alone to derive a base structural disposition model, with 1- 
2- and 3-compartment disposition models tested. It was assumed that bound drug is unavailable 
for elimination, distribution or pharmacological effect, so when total concentrations were added, 
free concentration (𝐶𝑈) was predicted from total concentration (𝐶𝑇) in the central compartment, with 





where 𝐵𝑚𝑎𝑥 and 𝐾𝑑 are the estimated Michaelis-Menten parameters, and 𝐶𝑇 = 𝐶𝑈 + 𝐶𝐵. The 




((𝐶𝑇 − 𝐵𝑚𝑎𝑥 − 𝐾𝑑) + √(𝐶𝑇 − 𝐵𝑚𝑎𝑥 − 𝐾𝑑)2 + 4𝐾𝑑𝐶𝑇) 
Metronidazole and hydroxymetronidazole were simultaneously fitted using the well-stirred liver 
model, using a similar model to previous study on oseltamivir carboxylate formation from 
oseltamivir31. A common absorption rate constant and fixed hepatic plasma flow were used to allow 
for both first-pass and hydroxymetronidazole formation from circulating drug to be identified. 
Structural and practical model identifiability is discussed in the Supplementary Material. Hepatic 
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plasma flow was derived from an allometrically scaled adult hepatic blood flow (73 L/h) scaled by 
measured hematocrit according to the expression reported by Price et al 36: 





(1 − ℎ0.91) 
where 𝑄𝐻𝑃 is hepatic plasma flow, w is body weight in kg and h is the hematocrit. The fraction 
transformed to hydroxymetronidazole during first-pass was assumed to be 1 minus the extraction 
ratio (𝐸𝑅) and hepatic clearance of circulating metronidazole to hydroxymetronidazole was given by 
the following: 




where the intrinsic clearance, 𝐶𝐿𝐼, was an estimated parameter. Clearance of metronidazole by 
other routes was assumed to be linear, as was clearance of hydroxymetronidazole. 
Biological prior information in the form of allometric scaling with exponents of 0.75, 1 and -0.25 for 
all clearance volume and absorption rate parameters respectively was added a priori. Furthermore 
a maturation function for renal clearance based on a previous study10 was used to scale free 
ceftriaxone clearance and hydroxymetronidazole clearance. Metronidazole hydroxylation at the 2 
position is catalyzed by CYP2A637, and hence the CYP2A6 maturation function reported by Upreti 
et al 11 was used to scale 𝐶𝐿𝐼. 
Further covariates tested in the following order were: albumin and total plasma protein on 𝐵𝑚𝑎𝑥, 
age corrected serum creatinine on free ceftriaxone clearance and hydroxymetronidazole 
clearance, and edema to scale weight in the allometric models. The likelihood ratio test was used 
to determine covariate inclusion, with an improvement in -2 log likelihood of >3.84 considered 
significant. Model diagnostics included plots of observations versus population predictions, 
conditional weighted residuals (CWRES) versus time and prediction, and individual profile plots. 
Simulation properties were tested with a Visual Predictive Check (VPC). Parameter stability was 
investigated using a non parametric bootstrap. Modelling was undertaken using NONMEM version 
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7.338 using the first-order conditional estimation algorithm with interaction (FOCEI). Perl-speaks 
NONMEM (PsN) was used for VPC and bootstrap preparation39, and data manipulations and 
plotting were performed using R version 3.2. 
Pharmacodynamic simulations 
A simulated population of 1000 subjects with demographics sampled from the study population 
was generated and the ceftriaxone model was used to simulate the 𝑓𝑇 > 𝑀𝐼𝐶 for MIC values in the 
range 0.25-8 mg/L. The 5th, 10th, 20th and 50th percentiles were presented to show the minimum 
𝑓𝑇 > 𝑀𝐼𝐶 for 95, 90 80 and 50 percent of patients respectively. A target of 0.5 for 𝑓𝑇 > 𝑀𝐼𝐶 with a 
MIC cut off of 2 mg/L (the current EUCAST resistance breakpoint) was considered. For 
metronidazole a pharmacodynamic target of Area Under the Curve to MIC ratio AUC(0-24)/MIC of 
708 and the 𝑓𝑇 > 𝑀𝐼𝐶 of 8 mg/L were investigated33. Simulations for once, twice and three-times 
daily dosing were performed, along with consideration of a loading dose. In these simulations 10% 
protein binding was assumed for parent and metabolite, and hydroxymetronidazole concentrations 
multiplied by 0.65 were added to metronidazole under the assumption of hydroxymetronidazole 
having 65% of its parent’s antimicrobial activity32. The results of all simulations for ceftriaxone and 
metronidazole were presented in a report to the FLACSAM trial steering committee to agree on 
dosing for the main trial. 
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Study Highlights 
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
There are no published pharmacokinetic data on ceftriaxone in infants and young children with 
severe acute malnutrition (SAM). A small study on oral metronidazole has been conducted, but no 
information on its major active metabolite is available. Changes in body composition and 
metabolism may affect the distribution and elimination of these agents. Inappropriate dosing may 
result in reduced efficacy, antimicrobial resistance or increased adverse effects. 
WHAT QUESTION DID THIS STUDY ADDRESS? 
What dose of ceftriaxone and metronidazole should be used in children with SAM who are sick and 
hospitalized? 
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? 
A dose of 80 mg/kg of ceftriaxone (rather than 50 mg/kg) is predicted to maximize target 
attainment. Twice daily metronidazole at 12.5 mg/kg (rather than 7.5 mg/kg three times daily) may 
provide a good compromise between achieving circulating target concentrations, maintaining 
adequate small intestinal concentrations, and reducing care giver time. Reduced serum albumin 
increased the unbound fraction of ceftriaxone. Edema significantly affected the disposition of both 
drugs with weight-based dosing leading to higher exposures, although this does not appear to 
warrant dose reduction. 
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE? 
Our data inform optimal dosing in this vulnerable group of children. Careful prospective study 
design enables pharmacokinetic parameter estimation of two drugs using only three post-dose 
samples. 
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Table legends 
Table 1: Demographics of all patients, and those included in the ceftriaxone and metronidazole 
pharmacokinetic analyzes. Median and range are presented for continuous variables. 
Table 2: Parameter estimates scaled to a 70 kg individual from the ceftriaxone and metronidazole 
models. Pharmacokinetic parameters for ceftriaxone relate to free concentrations, except V1 which 
is the total ceftriaxone central volume. CLIMET is the metronidazole intrinsic clearance to 
hydroxymetronidazole, CLMET is the apparent clearance of metronidazole by other routes, and 
CLOH the clearance of hydroxymetronidazole. Covariates entered the model as follows: BM = 
TVBM(Alb/33.75)θALB where Alb the individual albumin and 33.75 the median; CL = 
TVCL(SCR/MSCR)θSECR where SCR is the individual serum creatinine, and MSCR the expected 
serum creatinine for age;  WTC = WT(1+ θODEM_CEF or θODEM_MET) where WTC is the corrected 
weight for patients with edema used in the allometric scaling model. NONMEM code is provided in 
the Supplementary Material. 
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Figure legends 
Figure 1: Prediction corrected visual predictive check (VPC) for total and unbound ceftriaxone (top 
row) showing model simulated 95% confidence intervals for the simulated 2.5th, 50th and 97.5th 
percentiles. 
Figure 2: Prediction corrected visual predictive check (VPC) for metronidazole and 
hydroxymetronidazole showing model simulated 95% confidence intervals for the simulated 2.5th, 
50th and 97.5th percentiles. 
Figure 3: 𝑓𝑡 > 𝑀𝐼𝐶 for 50, 80 and 100 mg/kg once daily. The 5th, 10th, 20th and 50th percentiles 
show the cut-offs for 𝑓𝑡 > 𝑀𝐼𝐶 for 95, 90 80 and 50% of patients respectively. Lines at a MIC cut-
off of 2 mg/L and 𝑓𝑡 > 𝑀𝐼𝐶 of 0.5 show the proposed MIC target. 
Figure 4: Simulations for free metronidazole plus hydroxymetronidazole under 10, 12.5 and 15 
mg/kg twice daily (BD) dosing, with hydroxymetronidazole concentrations being multiplied by 0.65 
to reflect the assumed lower activity. A break-point of 8 mg/L is highlighted. Panel a. shows the 
𝑓𝑡 > 𝑀𝐼𝐶 with a value of 0.9 highlighted whereas panel b shows the AUC:MIC ratio with a cut-off of 
70 mg.h/L highlighted. A comparison of 24 and 48 hour target attainment is given in the upper and 
lower panels respectively. 
Figure 5: Box-plots to illustrate simulated covariate effects on translation to 𝑓𝑡 > 𝑀𝐼𝐶. Probability of 
target attainment reported beneath each box with a target of 50% of the dosing interval with 
concentrations above 2 mg/L at 24 hours for free ceftriaxone, and 90% of the dosing interval with 
concentrations of free metronidazole and 0.65 x hydroxymetronidazole above 8 mg/L at 48 hours. 
a. Effect of edema score of 1 or more on ceftriaxone target attainment; b. Effect of edema score of 
2 or more on metronidazole target attainment; c. Effect of serum creatinine on ceftriaxone target 
attainment. 
Supplementary Material 
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Table 1: Demographics of all patients, and those included in the ceftriaxone and 




All patients (n = 
81) 
Included in ceftriaxone 
analysis (n = 80) 
Included in metronidazole 
analysis (n = 69) 
Age (mo) 14(2-45) 15(2-45) 17(2-45) 
Weight (kg) 5.88(2.53-10.9) 5.88(2.53-10.9) 5.88(2.53-10.9) 
Sex (m/f) 35/46 35/45 30/39 
height (cm) 69.4(50.8-89) 69.7(50.8-89) 69.4(50.8-89) 
Na+ (mmol/L) 137(109-165) 137(109-165) 137(109-165) 
K+ (mmol/L) 3.8(0.7-7) 3.8(0.7-7) 3.9(0.7-7) 
Hemoglobin (g/dL) 9(4.4-12.8) 9(4.4-12.8) 9(4.4-12.8) 
WBC (x10^9/L) 14.1(4.8-58.1) 14.35(4.8-58.1) 13.5(4.8-58.1) 
Neutrophils 
(x10^9/L) 
5.27(1.2-66.4) 5.4(1.2-66.4) 5.27(1.2-66.4) 
Lymphocytes 
(x10^9/L) 
5.39(1.5-17.82) 5.36(1.5-17.82) 5.3(1.5-17.82) 
Platelets (x10^9/L) 397(19-775) 398(19-775) 375(19-775) 
Albumin (g/L) 33.6(7-57) 33.75(7-57) 30.7(7-57) 
Total protein (g/L) 59(11-92) 59(11-92) 58(11-90) 
creatinine 
(micromol/L) 
21(4-178) 21(4-178) 20(4-178) 
AST (IU/L) 53(6-758) 53(6-758) 52(6-270) 
edma grade 
(0/1/2/3) 
45/13/14/9 45/12/14/9 37/11/13/8 
median weight by 
edema grade (kg) 
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Table 2: Parameter estimates scaled to a 70 kg individual from the ceftriaxone and 
metronidazole models. Pharmacokinetic parameters for ceftriaxone relate to free 
concentrations, except V1 which is the total ceftriaxone central volume. CLIMET is the 
metronidazole intrinsic clearance to hydroxymetronidazole, CLMET is the apparent 
clearance of metronidazole by other routes, and CLOH the clearance of 
hydroxymetronidazole. Covariates entered the model as follows: BM = TVBM(Alb/33.75)θALB 
where Alb the individual albumin and 33.75 the median; CL = TVCL(SCR/MSCR)θSECR where 
SCR is the individual serum creatinine, and MSCR the expected serum creatinine for age;  
WTC = WT(1+ θODEM_CEF or θODEM_MET) where WTC is the corrected weight for patients with 





Estimate (bootstrap 95% 
CI) 




Ceftriaxone    
CL (L/h) 4.62(4.06,5.24) 42(33,49) 3.3 
V1 (L) 14.46(9.47,17.76) 43(28,71) 17.9 
 0.93(0.16,5.61) - - 
Q2 (L/h) 6.05(2.01,18.67) - - 
V2 (L) 29.98(20.32,68.15) - - 
Q3 (L/h) 19.26(12.39,25.98) - - 
V3 (L) 69.77(54.65,87.64) 42(26,55) 17.1 
BM (mg/h) 22.89(17.43,30.57) - - 
KD (mg/L) 0.56(0.21,0.92) - - 
θALB -0.26(-0.41,-0.12) - - 
θSECR -0.26(-0.36,-0.14) - - 
θODEM_CEF 27(19,33) - 21.4 
σPROP_FREE (%) 19(15,22) - 21.0 
σPROP_TOT (%) 4.62(4.06,5.24) 42(33,49) 3.3 
σADD_TOT (mg/L) 14.46(9.47,17.76) 43(28,71) 17.9 
Metronidazole    
Ka (/h) 0.39(0.29,0.6) 79(63,97) 13.9 
CLIMET (L/h) 0.74(0.51,1.08) 61(47,76) 5.2 
CLMET (L/h) 0.51(0.23,0.76) - - 
VMET (L) 56.35(47.73,65.48) 38(27,45) 18.3 
CLOH (L/h) 1.45(1.08,1.95) - - 
VOH (L) 16.89(11.67,24.77) - - 
Alag (h) 0.17(0.11,0.26) - - 
θODEM_MET -0.17(-0.31,-0.01) - - 
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σPROP_MET (%) 32(27,37) - 17.7 
σPROP_OHMET (%) 29(24,33) - 17.7 
σPROP_OHADD 
(mmol/L) 
0.01(0.002,0.04) - 17.7 
Covariates entered the model as follows: BM = TVBM(Alb/33.75)θALB where Alb the 
individual albumin and 33.75 the median; CL = TVCL(SCR/MSCR)θSECR where SCR is 
the individual serum creatinine, and MSCR the expected serum creatinine for age;  
WTC = WT(1+ θODEM_CEF or θODEM_MET) where WTC is the corrected weight for patients 
with edema used in the allometric scaling model. NONMEM code is provided in the 
Supplementary Material. 
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